How Emergent BioSolutions Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile

A spokesman for Mr. Blunt said he did not intervene on behalf of the company.

Meanwhile, the executive officer Warn Job losses at the factory in Lansing, Minnesota can occur. – A swing state capital at the center of a controversial presidential campaign between Mr. Trump and Hillary Clinton. In a call with federal officials, Amergent officials also said that the company may have to reduce and shut down the supply of some products in the stockpile, according to two public health officials who have publicly participated in the negotiations.

“They were putting on it – how poor they were and how it was going to ruin the company, and they would have to shut down factories, and America would be left without the anthrax vaccine,” said Rick Bright, one of the executives , Who topped both Obama and the Trump administration.

Dr. Lurie and Drs. For the health officials overseeing the stockpile, including Hatchet, who was also on call, it posed a bizarre question: Should they divert money to Emergent that might otherwise help prepare for other disasters?

Dr. Hatchet said the idea gave him pause. But, he explained in an interview, “If there is only one partner who can provide the product and there is only one customer for that product, then the customer needs the partner to survive.”

In the end, the government secured a $ 100 million bailout, dipping into the agency’s budget to develop new products for the stockpile, the Biomedical Advanced Research and Development Authority, known as BARDA. .

Just over a year later, Amergent spent about $ 200 million in cash, and, to meet other financial commitments, acquired Sanofi’s smallpox vaccine and GlaxoSmithKline’s anthrax treatment, two products with pipelines installed in the stockpile. The purchase expanded Emergent’s hold on the reserve.

Source link

Leave a Comment